Unichem gets USFDA nod for hypertension treatment tablets
The product is generic version of Merck Sharp & Dohme Corp's Cozaar tablets in the strength of 25 mg, 50 mg and 100 mg, Unichem said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 16, 2015 Category: Pharmaceuticals Source Type: news
Losartan Fails to Reduce LV Mass in HCM Patients: INHERITLosartan Fails to Reduce LV Mass in HCM Patients: INHERIT
The negative study does offer some good news, according to an editorial, in that losartan safely reduced blood pressure in patients with obstructive and nonobstructive HCM. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 30, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
Beta-Blocker, ARB Similarly Protective of Aorta in Marfan'sBeta-Blocker, ARB Similarly Protective of Aorta in Marfan's
There was no placebo in the trial that saw similar aortic-root dimension changes from treatment with atenolol or losartan. If standard therapy with atenolol helped, perhaps losartan did too? Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
AHA: Losartan Disappoints in Hypertrophic Cardiomyopathy (CME/CE)
(MedPage Today) -- ARB no better than placebo for reducing left ventricular hypertrophy. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 20, 2014 Category: Cardiology Source Type: news
The Marfan Foundation Comments on Study that Shows Losartan to be...
Provides New Option for Patients(PRWeb November 18, 2014)Read the full story at http://www.prweb.com/releases/MarfanTrial/11_18_2014/prweb12336271.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 20, 2014 Category: Pharmaceuticals Source Type: news
Losartan No Better Than Atenolol In Marfan's Syndrome
Beta-blockers have been the standard treatment for people with Marfan's syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people. The goal of treatment is to prevent or slow down the dilation of the aorta and avoid aortic dissection, the main cause of death. In recent years, studies have raised the hope that losartan, an angiotensin receptor blocker, might be more effective than beta-blockers in slowing aortic enlargement. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 19, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Atenolol vs Losartan in Patients With Marfan SyndromeAtenolol vs Losartan in Patients With Marfan Syndrome
Drs Bowen and Connolly discuss the results of a landmark head-to-head comparison of losartan vs atenolol in patients with Marfan syndrome. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 18, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Heart Drug, Losartan, Falls Short of Promise in a Study
The new study found there was no difference in the aortic growth rate between those taking losartan and those taking the standard treatment. (Source: NYT Health)
Source: NYT Health - November 18, 2014 Category: Consumer Health News Authors: By GINA KOLATA Tags: Marfan Syndrome Heart Blood Pressure Placebos Source Type: news
Studies Indicate that Losartan may be an effective treatment option for Marfan syndrome
Losartan blocks the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 18, 2014 Category: American Health Source Type: news
Kidney Cancer Patients on ASI Antihypertensives Live LongerKidney Cancer Patients on ASI Antihypertensives Live Longer
Kidney cancer patients who were taking captopril, lisinopril, losartan, and similar drugs for hypertension lived significantly longer than those who were not. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Blood pressure drug may enhance cancer treatment
A new study reveals that a common class of drug used to control high blood pressure could enhance cancer treatment by improving delivery of chemotherapy drugs and oxygen through tumors. A clinical trial is already in progress as a result of the study. Writing about their work in the online journal Nature Communications, researchers from Massachusetts General Hospital (MGH), an affiliate of Harvard Medical School, describe how the angiotensin inhibitor losartan increased blood flow and improved chemotherapy drug outcomes in mice with breast and pancreatic cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 3, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Cancer patients may benefit from repurposed hypertension med
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In their report in the online journal Nature Communications, Massachusetts General Hospital (MGH) investigators describe how the angiotensin inhibitor losartan improved the delivery of chemotherapy drugs and oxygen throughout tumors by increasing blood flow in mouse models of breast and pancreatic cancer. A clinical trial based on the findings of this study is now underway... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 3, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Common blood pressure drug losartan (Cozaar) reduces aortic enlargement in Marfan syndrome
A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome. Results of the COMPARE (COzaar in Marfan PAtients Reduces aortic Enlargement) study reveal that patients treated with losartan (Cozaar) had a significantly reduced rate of aortic enlargement after 3 years compared to patients who did not receive the treatment... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 4, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
ESC: Losartan Treatment Slows Aortic Dilation (CME/CE)
AMSTERDAM (MedPage Today) -- Aortic root dilation among Marfan's disease patients can be slowed by treatment with the angiotensin receptor blocker losartan (Cozaar), researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 2, 2013 Category: Cardiology Source Type: news
Tall Order: Losartan Looks Promising in Marfan SyndromeTall Order: Losartan Looks Promising in Marfan Syndrome
The lead investigator for the COMPARE study says, since blood-pressure lowering is already recommended in this group, losartan could be recommended to these patients. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
